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Summary
Background: Predictors of suboptimal coronary ﬂow in the infarct-related artery (IRA) after
stent-based primary percutaneous coronary intervention (PCI) in patients with acute myocardial
infarction (AMI) have not been fully investigated.
Methods and results: Using the AMI-Kyoto Multi-Center Risk Study database, we retro-Acute myocardial
infarction;
Stent;
No-reﬂow
spectively compared clinical manifestations and in-hospital prognosis between AMI patients
undergoing stent-based primary PCI with ﬁnal Thrombolysis In Myocardial Infarction (TIMI)
grade ≤2 in the IRA (nonoptimal group, n = 69) and those with ﬁnal TIMI grade 3 (opti-
mal group, n = 1200). The nonoptimal group had higher prevalence of Killip class ≥3
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at admission, higher frequency of mechanical support devices during procedures, larger value of
maximal creatine phosphokinase, and a signiﬁcantly higher in-hospital mortality rate (27.5% for
nonoptimal vs. 9.0% for optimal, P < 0.001), compared with the optimal group. On multivariate
analysis, Killip class ≥3 at admission was the independent predictor of the ﬁnal nonoptimal ﬂow
(odds ratio 2.33, 95% conﬁdence intervals 1.27—4.26 P = 0.006), but TIMI 3 ﬂow before primary
PCI and elapsed time (symptom onset-to-admission time) < 24 h were not.
Conclusions: Killip class ≥3 at admission is an independent predictor of the ﬁnal nonoptimal ﬂow
rimary PCI with stent implantation.
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nique. The coronary ﬂow in the IRA was graded according to
the classiﬁcation used in the TIMI trial. Signiﬁcant coronary
artery stenosis was deﬁned as at least a 75% reduction in thein AMI patients undergoing p
© 2009 Japanese College of C
ntroduction
rimary percutaneous coronary intervention (PCI) is now
stablished as a ﬁrst-line therapeutic strategy for patients
ith acute myocardial infarction (AMI). Prompt restoration
f optimal antegrade coronary ﬂow (Thrombolysis In Myocar-
ial Infarction [TIMI] grade 3) in the infarct-related artery
IRA) could limit infarct size and improve clinical outcome
n patients with AMI. Nevertheless, primary PCI is associ-
ted with 4—11% incidence of suboptimal coronary ﬂow (TIMI
rade ≤2), even in the coronary stent era [1—4], and fur-
hermore the suboptimal primary PCI result is related to
oor prognosis in AMI patients [5,6]. Speculated mechanisms
or this suboptimal epicardial coronary blood ﬂow include
ot only mechanical epicardial vessel obstruction, such as
igniﬁcant residual stenosis, dissection, or thrombus, but
lso coronary microcirculation disturbances, such as distal
mbolization of thrombus and plaque debris, microvascular
amage, or reperfusion injury. However, the clinical mani-
estations and the predictors of suboptimal postintervention
oronary ﬂow in AMI patients undergoing stent-based pri-
ary PCI have not been fully investigated. The AMI-Kyoto
ulti-Center Risk Study, a large multi-center observational
tudy in which collaborating hospitals in Kyoto Prefecture
ave collected demographic, procedural, and outcome data
n AMI patients, was established in 2000 in order to ana-
yze these data and build an emergency-hospital network
or heart diseases in Kyoto [7,8]. The purpose of the present
tudy is therefore to compare clinical background, angio-
raphic ﬁndings, and in-hospital prognosis between AMI
atients undergoing stent-based primary PCI with ﬁnal TIMI
rade ≤2 in the IRA and those with ﬁnal TIMI grade 3, using
ata from the AMI-Kyoto Multi-Center Risk Study.
ethods
atient population
rom January 2000 to December 2005, 2230 consecutive
atients with a diagnosis of AMI, who were admitted to AMI-
yoto Multi-Center Risk Study Group Hospitals within 1 week
fter the onset of AMI, were enrolled in the present study.
f these, 1817 patients received primary PCI, of whom data
n clinical background were available in 1785 and 1394 out
f the 1785 patients had stent implantation in the culprit
esions during primary PCI. Data on TIMI ﬂow grades in the
RA before/after primary PCI were available in 1269 out
f the 1394 patients undergoing stent-based primary PCI.
onoptimal coronary blood ﬂow was deﬁned as TIMI ≤2 ﬂow
nd optimal ﬂow as TIMI 3 ﬂow in the IRA at ﬁnal coronary
i
l
o
t
aology. Published by Elsevier Ireland Ltd. All rights reserved.
ngiography (CAG) after primary PCI. We retrospectively
ompared clinical background, coronary risk factors, angio-
raphic ﬁndings, and in-hospital prognosis between patients
ndergoing stent-based primary PCI with ﬁnal nonoptimal
ow in the IRA (nonoptimal group, n = 69) and patients with
nal optimal ﬂow (optimal group, n = 1200). The diagnosis of
MI required the presence of two of the following three cri-
eria: (1) characteristic clinical history; (2) serial changes
n the ECG suggesting infarction (Q-waves) or injury (ST-
egment elevations); and (3) transient increase in cardiac
nzymes to more than twofold the normal laboratory value.
ata collection
he patients’ demographic information, cardiovascular his-
ory, and risk factors (i.e., smoking, hypercholesterolemia,
ypertension, and diabetes mellitus) as well as the hos-
itals’ information were recorded. Hypercholesterolemia
as deﬁned as total cholesterol ≥220mg/dl or the use of
holesterol-lowering agents; hypertension was deﬁned as
ystemic blood pressure ≥140/90mmHg or the use of anti-
ypertensive treatment; diabetes mellitus was deﬁned as
asting blood sugar ≥126mg/dl or the use of speciﬁc treat-
ent. Sixteen collaborating hospitals were classiﬁed into
ow-volume hospitals and high-volume hospitals based on
he annual volume of primary PCI during the study period
nd the guidelines for PCI published by American Heart
ssociation, the American College of Cardiology, and the
ociety for Cardiovascular Angiography and Interventions in
005 [8,9]. After informed consent to participate in the
MI-Kyoto Multi-Center Risk Study was conﬁrmed by each
atient, all in-hospital data were transmitted to the cen-
er located at the Department of Cardiovascular Medicine in
yoto Prefectural University School of Medicine for analysis.
he study protocol was approved by each hospital’s ethics
ommittee.
mergency coronary angiography and reperfusion
herapy
mergency CAG was performed using the standard tech-nternal diameter of the right, left anterior descending, or
eft circumﬂex coronary arteries and their major branches,
r a 50% reduction in the internal diameter of the left main
runk (LMT). Non-signiﬁcant stenosis was deﬁned as coronary
rterial narrowing less than a signiﬁcant stenosis. Patients
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Table 1 Clinical characteristics of the study patients (the
nonoptimal group vs. the optimal group).
Nonoptimal
(n = 69)
Optimal
(n = 1200)
P
value
Age (mean years± SD) 69.9± 12.2 67.7± 12.1 0.137
Male (%) 47 (68.1) 900 (75.0) 0.201
Previous MI (%) 11 (15.9) 147 (12.3) 0.366
Previous PCI (%) 8 (11.6) 97 (8.1) 0.303
Previous CABG (%) 0 (0.0) 7 (0.6) 0.525
Risk factors
Smoking (%) 24 (34.8) 488 (40.7) 0.333
Hypercholesterolemia (%) 20 (29.0) 450 (37.5) 0.154
Hypertension (%) 38 (55.1) 620 (51.7) 0.582
Diabetes mellitus (%) 14 (20.3) 345 (28.8) 0.129
Elapsed time <24 h (%) 59 (85.5) 1058
(88.2)
0.508
Killip 3/4 (%) 18 (26.1) 145 (12.1) <0.001
Table 2 Angiographic ﬁndings and devices during primary
PCI of the study patients.
Nonoptimal
(n = 69)
Optimal
(n = 1200)
P-value
Culprit lesions
RCA (%) 24 (34.8) 427 (35.6) 0.460
LAD (%) 35 (50.7) 581 (48.4)
LCx (%) 7 (10.1) 150 (12.5)
LMT (%) 0 (0.0) 20 (1.7)
Multivessels (%) 3 (4.3) 22 (1.8)
No. of diseased vessels
1 (%) 38 (55.1) 681 (56.8) 0.698
2 (%) 23 (33.3) 366 (30.5)
3 (%) 8 (11.6) 132 (11.0)
LMT (%) 0 (0.0) 21 (1.8)
Pre TIMI grade
0 46 (66.7) 658 (54.8) 0.284
1 9 (13.0) 195 (16.3)
2 6 (8.7) 158 (13.2)
3 8 (11.6) 189 (15.8)
IABP (%) 36 (52.2) 169 (14.1) <0.001
PCPS (%) 4 (5.8) 18 (1.5) 0.008
Pacing (%) 9 (13.0) 120 (10.0) 0.416
RCA, right coronary artery; LAD, left anterior descending coro-
nary artery; LCx, left circumﬂex coronary artery; LMT, left
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tLow-volume hospital (%) 45 (65.2) 656 (54.7) 0.087
MI, myocardial infarction; PCI, percutaneous coronary interven-
tion; TIMI, thrombolysis in myocardial infarction.
with either angiographically normal coronary arteries or
non-signiﬁcant stenosis were classiﬁed as having zero-vessel
disease. Multivessels as culprit lesions were deﬁned as simul-
taneous thromboses of multiple coronary arteries in the
initial CAG. After the culprit lesions were ascertained by
CAG, primary PCI was subsequently performed.
Statistics
Data are expressed as mean± SD. The nonoptimal and the
optimal groups were compared using the chi-square test for
discrete variables and unpaired Student’s t-test for contin-
uous variables according to standard statistical methods.
The odds ratio and 95% conﬁdence intervals assessing the
ﬁnal TIMI 3 ﬂow after primary PCI were estimated by use of
multivariate logistic regression analysis. In all analyses, sig-
niﬁcance was accepted at P < 0.05. Statistical analysis was
performed with a standard statistical software (StatView,
version 5.0, SAS Institute Inc., Cary, NC, USA).
Results
Patient characteristics and risk factors
Of the 1269 AMI patients undergoing stent-based primary
PCI, 69 (5.4%) had TIMI ≤2 ﬂow after primary PCI. The num-
bers of patients with ﬁnal TIMI 0, 1, and 2 ﬂows were 13
patients (1.0%), 5 patients (0.4%), and 51 patients (4.0%),
respectively. The clinical characteristics and risk factors in
the nonoptimal group and the optimal group are summarized
in Table 1. The nonoptimal group had higher frequency of
Killip class ≥3 at admission than the optimal group. The
nonoptimal group had higher prevalence of receiving PCI
at low-volume hospitals, compared with the optimal group,
although the difference was not signiﬁcant. The prevalence
of elapsed time (symptom onset-to-admission time) < 24 h
v
t
h
ﬁmain trunk; SVG, saphenous vein graft; TIMI, thrombolysis in
myocardial infarction; IABP, intraaortic balloon pumping; PCPS,
percutaneous cardiopulmonary support.
nd coronary risk factors did not differ between the two
roups.
ngiographic data and devices during coronary
ntervention
able 2 shows the results of emergency CAG and mechan-
cal assist devices during primary PCI in the two groups.
he distributions of culprit lesions, number of diseased ves-
els, and TIMI grade before PCI did not differ between
he two groups. The nonoptimal group was more likely to
ave intraaortic balloon pumping and percutaneous car-
iopulmonary support during procedures, compared with
he nonoptimal group.
n-hospital outcomes
able 3 shows the in-hospital prognosis in the two groups.
he nonoptimal group had a signiﬁcantly higher in-hospital
verall mortality rate and signiﬁcantly higher incidence
f cardiac-related death than the optimal group. Among
atients with Killip 1-2, the patients with ﬁnal TIMI ≤2
n = 51) had a signiﬁcantly higher in-hospital overall mor-
ality than the patients with ﬁnal TIMI 3 (n = 1055) (13.7%
s. 4.5%, P = 0.0027), while among patients with Killip 3—4,
he patients with ﬁnal TIMI ≤2 (n = 18) had a signiﬁcantly
igher in-hospital overall mortality than the patients with
nal TIMI 3 (n = 145) (66.7% vs. 42.1%, P = 0.0478). Thus,
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Table 3 In-hospital outcomes in the study patients.
Nonoptimal (n = 69) Optimal (n = 1200) P-value
Length of hospital stay (days) 22.7± 19.4 22.3± 17.8 0.863
max CK (IU/l) 3862.5± 3746.7 2691.9± 2772.9 0.001
Death (%) 19 (27.5) 108 (9.0) <0.001
Cardiac-related (%) 16 (23.2) 78 (6.5) <0.001
Shock 6 33 0.005
Heart failure 7 28 <0.001
Rupture 2 9 0.061
Vf 1 8 0.451
Noncardiac-related (%) 3 (4.3) 30 (2.5) 0.348
ax CK available only for 64 of the nonoptimal group and for 1166 of
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Table 4 Predictors of ﬁnal nonoptimal ﬂow (ﬁnal TIMI ≤2
ﬂow) in the study patients (multivariate logistic regression
analysis).
OR 95% CI P-value
Killip 3/4 2.329 1.274—4.259 0.0060
Low-volume hospital 1.488 0.885—2.501 0.1339
Previous MI 1.327 0.667—2.638 0.4202
Hypertension 1.257 0.758—2.085 0.3756
Elapsed time < 24 h 0.819 0.402—1.667 0.5819
TIMI 3 before PCI 0.673 0.314—1.442 0.3081
Diabetes mellitus 0.611 0.332—1.126 0.1140
Age 1.002 0.979—1.026 0.8711
OR, odds ratio; CI, conﬁdence intervals; MI, myocardial
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aCK, creatine phosphokinase; Vf, ventricular ﬁbrillation. Data on m
the optimal group.
rrespective of Killip grade at admission, patients with ﬁnal
IMI ≤2 ﬂow after PCI had a higher in-hospital mortal-
ty rate than those with ﬁnal TIMI 3 ﬂow. Additionally,
he nonoptimal group had signiﬁcantly higher prevalence
f death ascribed to cardiogenic shock and heart fail-
re than the optimal group, whereas the incidence of
eaths derived from cardiac rupture and ventricular ﬁb-
illation did not differ between the two groups. Data
n maximal creatine phosphokinase (CK) were available
nly for 64 of the nonoptimal group and for 1166 of
he optimal group. The nonoptimal group had higher val-
es of maximal CK than the optimal group, whereas the
ength of hospital stay did not differ between the two
roups.
redictors of nonoptimal ﬂow after primary PCI
n order to assess the contribution of clinical background,
isk factors, and angiographic ﬁndings, a multivariate
ogistic regression analysis using all available variables
age, gender, previous myocardial infarction, smoking,
ypercholesterolemia, hypertension, diabetes mellitus,
ultivessels or LMT as culprit lesions, number of diseased
essels ≥2 or diseased LMT, elapsed time <24 h, Killip class
3 at admission, TIMI 3 ﬂow before primary PCI, low-volume
ospital) was developed for ﬁnal nonoptimal ﬂow in the IRA
fter primary PCI (Table 4). Killip class ≥3 at admission was
he only independent predictor of the nonoptimal ﬂow in the
RA immediately after primary PCI with stent implantation.
iscussion
he major ﬁndings of the present multi-center study are
s follows: (1) among AMI patients undergoing primary PCI
ith stent implantation, the patients with ﬁnal nonoptimal
ow (ﬁnal TIMI ≤2 ﬂow) in the IRA had an approximately
hreefold higher in-hospital mortality rate, compared with
he patients with ﬁnal optimal ﬂow (ﬁnal TIMI 3 ﬂow); (2)
ccording to the results of multivariate analysis, Killip class
3 at admission was the independent predictor of ﬁnal
onoptimal ﬂow in this population.
Some previous reports involving AMI patients undergoing
rimary PCI with less usage of coronary stent have indicated
t
l
s
r
dinfarction; TIMI, thrombolysis in myocardial infarction; PCI, per-
cutaneous coronary intervention.
he lack of preinfarction angina, number of Q-waves on elec-
rocardiogram before PCI, TIMI 0, 1 ﬂow at initial CAG,
nterior location of myocardial infarction, hyperglycemia,
nd longer elapsed time as clinical and angiographic predic-
ors of ﬁnal TIMI ≤2 ﬂow or no-reﬂow phenomenon in the IRA
6,10—12]. However, data regarding predictors of ﬁnal TIMI
2 ﬂow after stent-based primary PCI has been still limited.
recent report from Brosh and colleagues demonstrated
hat renal failure (creatinine ≥1.5mg/dl) and initial TIMI ≤1
ow were independent predictors of ﬁnal TIMI ≤2 ﬂow in AMI
atients undergoing stent-based primary PCI [4]. Another
ecent report from Japanese investigators has pointed out
hat ﬁbrofatty-rich component with necrotic core or dense
alcium based on virtual histology intravascular ultrasound
s closely related to ﬁnal TIMI ≤2 ﬂow after primary PCI with
tent [13]. In the present multi-center study, we have shown
hat Killip class ≥3 at admission was the independent pre-
ictor of the nonoptimal ﬂow (TIMI ≤2) after stent-based
rimary PCI. AMI patients with Killip class ≥3 at admission
re frequently accompanied by severely impaired left ven-
ricular function. Previous studies have also indicated that
eft ventricular ejection fraction (LVEF) <50%, cardiogenic
hock, and increased heart rate were also independent cor-
elates of ﬁnal TIMI ≤2 ﬂow, suggesting that left ventricular
ysfunction might be closely related to ﬁnal nonoptimal ﬂow
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[6,10,14]. Thus it is reasonable to propose that Killip class
≥3 at admission with lower LVEF, which might be attributed
to broad infarction, could have large microvascular bed
injury, increased left ventricular end-diastolic pressure, and
decreased coronary perfusion pressure, leading to resultant
nonoptimal coronary ﬂow.
On the contrary, in the present report TIMI 3 ﬂow
prior to primary PCI, and elapsed time (symptom onset-to-
admission time) <24 h were not associated with the ﬁnal
nonoptimal coronary ﬂow after primary PCI, inconsistent
with previous studies [6,10,14—16]. TIMI 3 ﬂow prior to pri-
mary PCI resulting from spontaneous recanalization might
enhance endogenous thrombolysis and resolution of coro-
nary spasm, and could therefore prevent large infarction,
distal embolization of thrombus, and microvascular spasm,
leading to ﬁnal TIMI 3 ﬂow. Similarly, longer ischemic time
might lead to larger myocardial damage associated with
greater microvascular injury and enhance larger as well as
highly organized intracoronary thrombus formation, which
may contribute to distal embolization, impaired microcir-
culation, and resultant nonoptimal coronary ﬂow during
primary PCI. Although these concepts support the useful-
ness of antecedent thrombolytic therapy before PCI, the
role of facilitated PCI remains uncertain [17,18]. We cannot
explain those discrepant data between the present report
and previous ones precisely, however, we cannot rule out
the possibility that recent aggressive employments of aspi-
ration catheter before stent implantation during primary PCI
might cancel the advantage of TIMI 3 ﬂow prior to primary
PCI, and elapsed time (symptom onset-to-admission time)
<24 h in the achievement of ﬁnal TIMI 3 ﬂow. In addition,
the elapsed time (symptom onset-to-admission time) in our
present report was different from symptom onset-to-balloon
time and therefore might not reﬂect the real ‘‘ischemic
time’’ precisely.
Recently we have demonstrated that angiographic results
of primary PCI in high-volume hospitals were superior to
those in low-volume hospitals, which were estimated by
TIMI ﬂow grade [8]. Despite lower TIMI ﬂow grade in the
IRA before PCI, high-volume hospitals had higher acquisition
rates of TIMI ﬂow grade 3 just after PCI than low-volume
hospitals [8]. Moreover, there was a trend toward higher
frequency of emergency CABG due to failed primary PCI
in AMI patients treated at low-volume hospitals [8]. In our
present study, however, treatment at low-volume hospitals
was not the independent predictor of the nonoptimal ﬂow
after stent-based primary PCI. Further studies are indispens-
able to examine the relation between the annual hospital
volume of primary PCI and ﬁnal optimal coronary ﬂow in
AMI patients undergoing primary PCI.
Our present ﬁndings and previous ones suggest that a
careful and aggressive attempt to obtain optimal ﬂow in the
IRA should be made in AMI patients complicated with con-
gestive heart failure or cardiogenic shock. Primary stenting
combined with adjunctive therapies such as intracoronary
administration of nicorandil, verapamil, or nitroprusside as
well as intravenous administration of nicorandil or newer
antiplatelet agents might play an important role in achiev-
ing not only optimal epicardial coronary blood ﬂow but
also adequate peripheral microcirculation in those high-risk
AMI patients [2,3,15,19,20]. Additionally, although effects
of routine usage of aspiration catheter or distal protec-
w
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ion device in minimizing distal embolization of thrombus
nd plaque debris and achieving ﬁnal optimal ﬂow in the
RA remains controversial, these devices might be also
ecessary particularly in the high-risk AMI patients with
ongestive heart failure or cardiogenic shock [18,21—23].
urther studies are necessary to establish the modality to
ssess myocardial reperfusion at the tissue level and to
xamine the appropriate PCI strategy to obtain ﬁnal optimal
oronary ﬂow in this population.
tudy limitation
irst, this is a retrospective observational analysis of a rel-
tively small number of patients. Second, data on clinical
ackground and angiographic results of primary PCI were not
vailable for all AMI patients undergoing primary PCI. Third,
e have not accounted for left ventricular function and door
o balloon time, which might be a strong correlates of ﬁnal
onoptimal coronary ﬂow. Fourth, ‘‘ST-elevation MI’’ was
ot discriminated from ‘‘non-ST-elevation MI’’. Fifth, we
ad no data regarding frequency of thrombectomy catheter
sage, laboratory data at admission, medications before
CI, and pharmacological treatment during PCI, which might
ffect achievement of TIMI 3. Sixth, we had no detailed data
egarding elapsed time among the study population. In addi-
ion, the inclusion criteria ‘‘the admission within one week
fter the onset of AMI’’ in the present report might be inap-
ropriate to evaluate the results of primary PCI, because
he recent report by Hochman et al. indicated that pri-
ary PCI did not improve the mortality if it is performed
ater than 24 h after the onset of AMI [24]. However, pri-
ary PCI are performed in some cases with elapsed time
24 h in the ‘‘real world’’ and according to the guidelines
or PCI published by the American Heart Association, the
merican College of Cardiology, and the Society for Cardio-
ascular Angiography and Interventions in 2005, primary PCI
ould be tolerated beyond 12 h after symptom onset in AMI
atients with shock, hemodynamic or electrical instability,
evere heart failure, or evidence of persistent ischemia [9].
oreover, such cases with late reperfusion tend to have high
isk of slow/no reﬂow. Thus, the inclusion criteria in our
resent report might be one of the options for evaluating
he predictor of suboptimal coronary ﬂow during primary
CI. Furthermore, we could not distinguish no-reﬂow phe-
omenon from mechanical epicardial vessel obstruction due
o a signiﬁcant residual stenosis, dissection, or thrombus
s the cause of the nonoptimal coronary ﬂow. However, all
he study population underwent stent implantation during
rimary PCI and thus we speculated that most of the nonop-
imal ﬂow might be derived from no-reﬂow phenomenon,
ut not from epicardial vessel closure.
onclusion
he present study provides evidence that among AMI
atients undergoing stent-based primary PCI, the patients
ith ﬁnal nonoptimal ﬂow (ﬁnal TIMI ≤2 ﬂow) had an
pproximately threefold higher in-hospital mortality rate,
ompared with the patients with ﬁnal optimal ﬂow (ﬁnal
IMI 3 ﬂow) and Killip class ≥3 at admission was the inde-
endent predictor of the ﬁnal nonoptimal ﬂow in the IRA.
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owever, the small size of the study population as well as
he lack of data regarding left ventricular function are major
imitations, so a larger and more detailed study should be
erformed to conﬁrm our ﬁndings.
ppendix A.
he following institutions and principal investigators par-
icipated in the present study as the AMI-Kyoto Multi-Center
isk Study Group: Kyoto City Hospital: Matsubara K, Shima M,
iyama M, Nakajima N; Kyoto Kidugawa Hospital: Miyanaga
, Nakagawa T, Matsui H, Kunieda Y; Kyoto Second Red Cross
ospital: Fujita H, Inoue K, Matsuo A, Sakatani T, Tsubaki-
oto Y; Social Insurance Kyoto Hospital: Yamada C, Oda
, Tanabe S; Nantan General Hospital: Tatsumi T, Keira N,
ishikawa S, Nomura T; Ayabe Municipal Hospital: Shiga K,
ohno Y, Adachi Y, Yokoi H; Kameoka Municipal Hospital:
uriyama T, Matsuo R; Maizuru Medical Center: Harada Y,
ikosaka T, Nakagami T; Kyoto Saiseikai Hospital: Yama-
ara Y, Ishibashi K; Gakkentoshi Hospital: Sakai R, Akashi K;
iseikai Yamashina Hospital: Yamamoto T; Kouseikai Takeda
ospital: Kinoshita N, Irie H, Nakamura R; Fukuchiyama
unicipal Hospital: Nishio M, Sakamoto T, Hayashi H, Mat-
unaga S; Kyoto Prefectural Yosanoumi Hospital: Kimura S,
sodono K, Honsho S, Tagawa M, Takada H; Kyoto First Red
ross Hospital: Matsui A, Ariyoshi M, Kimura M; Kyoto Pre-
ectural University School of Medicine: Takahashi T, Shiraishi
, Yamano T.
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